Skip to main content
Top
Published in: BMC Cancer 1/2018

Open Access 01-12-2018 | Research article

Development of a normal tissue complication probability (NTCP) model for radiation-induced hypothyroidism in nasopharyngeal carcinoma patients

Authors: Ren Luo, Vincent W. C. Wu, Binghui He, Xiaoying Gao, Zhenxi Xu, Dandan Wang, Zhining Yang, Mei Li, Zhixiong Lin

Published in: BMC Cancer | Issue 1/2018

Login to get access

Abstract

Background

The objectives of this study were to build a normal tissue complication probability (NTCP) model of radiation-induced hypothyroidism (RHT) for nasopharyngeal carcinoma (NPC) patients and to compare it with other four published NTCP models to evaluate its efficacy.

Methods

Medical notes of 174 NPC patients after radiotherapy were reviewed. Biochemical hypothyroidism was defined as an elevated level of serum thyroid-stimulating hormone (TSH) value with a normal or decreased level of serum free thyroxine (fT4) after radiotherapy. Logistic regression with leave-one-out cross-validation was performed to establish the NTCP model. Model performance was evaluated and compared by the area under the receiver operating characteristic curve (AUC) in our NPC cohort.

Results

With a median follow-up of 24 months, 39 (22.4%) patients developed biochemical hypothyroidism. Gender, chemotherapy, the percentage thyroid volume receiving more than 50 Gy (V50), and the maximum dose of the pituitary (Pmax) were identified as the most predictive factors for RHT. A NTCP model based on these four parameters were developed. The model comparison was made in our NPC cohort and our NTCP model performed better in RHT prediction than the other four models.

Conclusions

This study developed a four-variable NTCP model for biochemical hypothyroidism in NPC patients post-radiotherapy. Our NTCP model for RHT presents a high prediction capability.

Trial registration

This is a retrospective study without registration.
Appendix
Available only for authorised users
Literature
1.
go back to reference Rønjom: Radiation-induced hypothyroidism after treatment of head and neck cancer. 2015. Rønjom: Radiation-induced hypothyroidism after treatment of head and neck cancer. 2015.
2.
go back to reference Lin ZX, Yang ZN, Zhan YZ, Xie WJ, Li GW, Feng HT. Application study of the 2008 staging system of nasopharyngeal carcinoma. Ai Zheng. 2009;28(10):1029–32.PubMed Lin ZX, Yang ZN, Zhan YZ, Xie WJ, Li GW, Feng HT. Application study of the 2008 staging system of nasopharyngeal carcinoma. Ai Zheng. 2009;28(10):1029–32.PubMed
3.
go back to reference Wu YH, Wang HM, Chen HH, Lin CY, Chen EY, Fan KH, Huang SF, Chen IH, Liao CT, Cheng AJ, et al. Hypothyroidism after radiotherapy for nasopharyngeal cancer patients. Int J Radiat Oncol Biol Phys. 2010;76(4):1133–9.CrossRefPubMed Wu YH, Wang HM, Chen HH, Lin CY, Chen EY, Fan KH, Huang SF, Chen IH, Liao CT, Cheng AJ, et al. Hypothyroidism after radiotherapy for nasopharyngeal cancer patients. Int J Radiat Oncol Biol Phys. 2010;76(4):1133–9.CrossRefPubMed
4.
go back to reference Lin Z, Wu VW, Lin J, Feng H, Chen L. A longitudinal study on the radiation-induced thyroid gland changes after external beam radiotherapy of nasopharyngeal carcinoma. Thyroid. 2011;21(1):19–23.CrossRefPubMed Lin Z, Wu VW, Lin J, Feng H, Chen L. A longitudinal study on the radiation-induced thyroid gland changes after external beam radiotherapy of nasopharyngeal carcinoma. Thyroid. 2011;21(1):19–23.CrossRefPubMed
5.
go back to reference Huang S, Wang X, Hu C, Ying H. Hypothalamic–pituitary–thyroid dysfunction induced by intensity-modulated radiotherapy (IMRT) for adult patients with nasopharyngeal carcinoma. Med Oncol. 2013;30(4):710.CrossRefPubMed Huang S, Wang X, Hu C, Ying H. Hypothalamic–pituitary–thyroid dysfunction induced by intensity-modulated radiotherapy (IMRT) for adult patients with nasopharyngeal carcinoma. Med Oncol. 2013;30(4):710.CrossRefPubMed
6.
go back to reference Lee V, Chan SY, Choi CW, Kwong D, Lam KO, Tong CC, Sze CK, Ng S, Leung TW, Lee A. Dosimetric predictors of hypothyroidism after radical intensity-modulated radiation therapy for non-metastatic nasopharyngeal carcinoma. Clin Oncol. 2016;28(8):e52–60.CrossRef Lee V, Chan SY, Choi CW, Kwong D, Lam KO, Tong CC, Sze CK, Ng S, Leung TW, Lee A. Dosimetric predictors of hypothyroidism after radical intensity-modulated radiation therapy for non-metastatic nasopharyngeal carcinoma. Clin Oncol. 2016;28(8):e52–60.CrossRef
7.
go back to reference Chua ML, Wee JT, Hui EP, Chan AT. Nasopharyngeal carcinoma. Lancet (London, England). 2016;387(10022):1012–24.CrossRef Chua ML, Wee JT, Hui EP, Chan AT. Nasopharyngeal carcinoma. Lancet (London, England). 2016;387(10022):1012–24.CrossRef
8.
go back to reference Alterio D, Jereczek-Fossa BA, Franchi B, D’Onofrio A, Piazzi V, Rondi E, Ciocca M, Gibelli B, Grosso E, Tradati N, et al. Thyroid disorders in patients treated with radiotherapy for head-and-neck cancer: a retrospective analysis of seventy-three patients. Int J Radiat Oncol Biol Phys. 2007;67(1):144–50.CrossRefPubMed Alterio D, Jereczek-Fossa BA, Franchi B, D’Onofrio A, Piazzi V, Rondi E, Ciocca M, Gibelli B, Grosso E, Tradati N, et al. Thyroid disorders in patients treated with radiotherapy for head-and-neck cancer: a retrospective analysis of seventy-three patients. Int J Radiat Oncol Biol Phys. 2007;67(1):144–50.CrossRefPubMed
9.
go back to reference Ling S, Bhatt AD, Brown NV, Nguyen P, Sipos JA, Chakravarti A, Rong Y. Correlative study of dose to thyroid and incidence of subsequent dysfunction after head and neck radiation. Head Neck. 2017;39(3):548–54.CrossRefPubMed Ling S, Bhatt AD, Brown NV, Nguyen P, Sipos JA, Chakravarti A, Rong Y. Correlative study of dose to thyroid and incidence of subsequent dysfunction after head and neck radiation. Head Neck. 2017;39(3):548–54.CrossRefPubMed
10.
go back to reference Murthy V, Narang K, Ghosh-Laskar S, Gupta T, Budrukkar A, Agrawal JP. Hypothyroidism after 3-dimensional conformal radiotherapy and intensity-modulated radiotherapy for head and neck cancers: prospective data from 2 randomized controlled trials. Head Neck. 2014;36(11):1573–80.CrossRefPubMed Murthy V, Narang K, Ghosh-Laskar S, Gupta T, Budrukkar A, Agrawal JP. Hypothyroidism after 3-dimensional conformal radiotherapy and intensity-modulated radiotherapy for head and neck cancers: prospective data from 2 randomized controlled trials. Head Neck. 2014;36(11):1573–80.CrossRefPubMed
11.
go back to reference Sommat K, Ong WS, Hussain A, Soong YL, Tan T, Wee J, Fong KW: Thyroid V40 Predicts Primary Hypothyroidism Following Intensity Modulated Radiotherapy for Nasopharyngeal Carcinoma. International Journal of Radiation Oncology • Biology • Physics (in Press). Sommat K, Ong WS, Hussain A, Soong YL, Tan T, Wee J, Fong KW: Thyroid V40 Predicts Primary Hypothyroidism Following Intensity Modulated Radiotherapy for Nasopharyngeal Carcinoma. International Journal of Radiation Oncology • Biology • Physics (in Press).
12.
go back to reference Zhai RP, Kong FF, Du CR, Hu CS, Ying HM. Radiation-induced hypothyroidism after IMRT for nasopharyngeal carcinoma: clinical and dosimetric predictors in a prospective cohort study. Oral Oncol. 2017;68:44–9.CrossRefPubMed Zhai RP, Kong FF, Du CR, Hu CS, Ying HM. Radiation-induced hypothyroidism after IMRT for nasopharyngeal carcinoma: clinical and dosimetric predictors in a prospective cohort study. Oral Oncol. 2017;68:44–9.CrossRefPubMed
13.
go back to reference Grande C. Hypothyroidism following radiotherapy for head and neck cancer: multivariate analysis of risk factors. Radiother Oncol. 1992;25(1):31–6.CrossRefPubMed Grande C. Hypothyroidism following radiotherapy for head and neck cancer: multivariate analysis of risk factors. Radiother Oncol. 1992;25(1):31–6.CrossRefPubMed
14.
go back to reference Boomsma MJ, Bijl HP, Christianen ME, Beetz I, Chouvalova O, Steenbakkers RJ, van der Laan BF, Wolffenbuttel BH, Oosting SF, Schilstra C, et al. A prospective cohort study on radiation-induced hypothyroidism: development of an NTCP model. Int J Radiat Oncol Biol Phys. 2012;84(3):e351–6.CrossRefPubMed Boomsma MJ, Bijl HP, Christianen ME, Beetz I, Chouvalova O, Steenbakkers RJ, van der Laan BF, Wolffenbuttel BH, Oosting SF, Schilstra C, et al. A prospective cohort study on radiation-induced hypothyroidism: development of an NTCP model. Int J Radiat Oncol Biol Phys. 2012;84(3):e351–6.CrossRefPubMed
15.
go back to reference Cella L, Conson M, Caterino M, De Rosa N, Liuzzi R, Picardi M, Grimaldi F, Solla R, Farella A, Salvatore M, et al. Thyroid V30 predicts radiation-induced hypothyroidism in patients treated with sequential chemo-radiotherapy for Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys. 2012;82(5):1802–8.CrossRefPubMed Cella L, Conson M, Caterino M, De Rosa N, Liuzzi R, Picardi M, Grimaldi F, Solla R, Farella A, Salvatore M, et al. Thyroid V30 predicts radiation-induced hypothyroidism in patients treated with sequential chemo-radiotherapy for Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys. 2012;82(5):1802–8.CrossRefPubMed
16.
go back to reference Cella L, Liuzzi R, Conson M, D'Avino V, Salvatore M, Pacelli R. Development of multivariate NTCP models for radiation-induced hypothyroidism: a comparative analysis. Radiat Oncol. 2012;7:224.CrossRefPubMedPubMedCentral Cella L, Liuzzi R, Conson M, D'Avino V, Salvatore M, Pacelli R. Development of multivariate NTCP models for radiation-induced hypothyroidism: a comparative analysis. Radiat Oncol. 2012;7:224.CrossRefPubMedPubMedCentral
17.
go back to reference Ronjom MF, Brink C, Bentzen SM, Hegedus L, Overgaard J, Johansen J. Hypothyroidism after primary radiotherapy for head and neck squamous cell carcinoma: normal tissue complication probability modeling with latent time correction. Radiother Oncol. 2013;109(2):317–22.CrossRefPubMed Ronjom MF, Brink C, Bentzen SM, Hegedus L, Overgaard J, Johansen J. Hypothyroidism after primary radiotherapy for head and neck squamous cell carcinoma: normal tissue complication probability modeling with latent time correction. Radiother Oncol. 2013;109(2):317–22.CrossRefPubMed
18.
go back to reference Kim MY, Yu T, Wu HG. Dose-volumetric parameters for predicting hypothyroidism after radiotherapy for head and neck Cancer. Jpn J Clin Oncol. 2014;44(4):331–7.CrossRefPubMed Kim MY, Yu T, Wu HG. Dose-volumetric parameters for predicting hypothyroidism after radiotherapy for head and neck Cancer. Jpn J Clin Oncol. 2014;44(4):331–7.CrossRefPubMed
19.
go back to reference Sachdev S, Refaat T, Bacchus ID, Sathiaseelan V, Mittal BB. Thyroid V50 highly predictive of hypothyroidism in head-and-neck cancer patients treated with intensity-modulated radiotherapy (IMRT). Am J Clin Oncol. 2014. [Epub ahead of print]. Sachdev S, Refaat T, Bacchus ID, Sathiaseelan V, Mittal BB. Thyroid V50 highly predictive of hypothyroidism in head-and-neck cancer patients treated with intensity-modulated radiotherapy (IMRT). Am J Clin Oncol. 2014. [Epub ahead of print].
20.
go back to reference Fujiwara M, Kamikonya N, Odawara S, Suzuki H, Niwa Y, Takada Y, Doi H, Terada T, Uwa N, Sagawa K, et al. The threshold of hypothyroidism after radiation therapy for head and neck cancer: a retrospective analysis of 116 cases. J Radiat Res. 2015;56(3):577–82.CrossRefPubMedPubMedCentral Fujiwara M, Kamikonya N, Odawara S, Suzuki H, Niwa Y, Takada Y, Doi H, Terada T, Uwa N, Sagawa K, et al. The threshold of hypothyroidism after radiation therapy for head and neck cancer: a retrospective analysis of 116 cases. J Radiat Res. 2015;56(3):577–82.CrossRefPubMedPubMedCentral
21.
go back to reference El Naqa I, Bradley J, Blanco AI, Lindsay PE, Vicic M, Hope A, Deasy JO. Multivariable modeling of radiotherapy outcomes, including dose-volume and clinical factors. Int J Radiat Oncol Biol Phys. 2006;64(4):1275–86.CrossRefPubMed El Naqa I, Bradley J, Blanco AI, Lindsay PE, Vicic M, Hope A, Deasy JO. Multivariable modeling of radiotherapy outcomes, including dose-volume and clinical factors. Int J Radiat Oncol Biol Phys. 2006;64(4):1275–86.CrossRefPubMed
22.
go back to reference Luo R, Li M, Yang Z, Zhan Y, Huang B, Lu J, Xu Z, Lin Z. Nomogram for radiation-induced hypothyroidism prediction in nasopharyngeal carcinoma after treatment. Br J Radiol. 2016;90(1070):20160686.CrossRefPubMed Luo R, Li M, Yang Z, Zhan Y, Huang B, Lu J, Xu Z, Lin Z. Nomogram for radiation-induced hypothyroidism prediction in nasopharyngeal carcinoma after treatment. Br J Radiol. 2016;90(1070):20160686.CrossRefPubMed
23.
go back to reference Lee N, Harris J, Garden AS, Straube W, Glisson B, Xia P, Bosch W, Morrison WH, Quivey J, Thorstad W, et al. Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225. J Clin Oncol. 2009;27(22):3684–90.CrossRefPubMedPubMedCentral Lee N, Harris J, Garden AS, Straube W, Glisson B, Xia P, Bosch W, Morrison WH, Quivey J, Thorstad W, et al. Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225. J Clin Oncol. 2009;27(22):3684–90.CrossRefPubMedPubMedCentral
24.
go back to reference DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44(3):837–45.CrossRefPubMed DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44(3):837–45.CrossRefPubMed
25.
go back to reference Chyan A, Chen J, Shugard E, Lambert L, Quivey JM, Yom SS. Dosimetric predictors of hypothyroidism in oropharyngeal cancer patients treated with intensity-modulated radiation therapy. Radiat Oncol. 2014;9:269.CrossRefPubMedPubMedCentral Chyan A, Chen J, Shugard E, Lambert L, Quivey JM, Yom SS. Dosimetric predictors of hypothyroidism in oropharyngeal cancer patients treated with intensity-modulated radiation therapy. Radiat Oncol. 2014;9:269.CrossRefPubMedPubMedCentral
26.
go back to reference Akgun Z, Atasoy BM, Ozen Z, Yavuz D, Gulluoglu B, Sengoz M, Abacioglu U. V30 as a predictor for radiation-induced hypothyroidism: a dosimetric analysis in patients who received radiotherapy to the neck. Radiat Oncol. 2014;9:104.CrossRefPubMedPubMedCentral Akgun Z, Atasoy BM, Ozen Z, Yavuz D, Gulluoglu B, Sengoz M, Abacioglu U. V30 as a predictor for radiation-induced hypothyroidism: a dosimetric analysis in patients who received radiotherapy to the neck. Radiat Oncol. 2014;9:104.CrossRefPubMedPubMedCentral
27.
go back to reference Diaz R, Jaboin JJ, Morales-Paliza M, Koehler E, Phillips JG, Stinson S, Gilbert J, Chung CH, Murphy BA, Yarbrough WG, et al. Hypothyroidism as a consequence of intensity-modulated radiotherapy with concurrent taxane-based chemotherapy for locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2010;77(2):468–76.CrossRefPubMed Diaz R, Jaboin JJ, Morales-Paliza M, Koehler E, Phillips JG, Stinson S, Gilbert J, Chung CH, Murphy BA, Yarbrough WG, et al. Hypothyroidism as a consequence of intensity-modulated radiotherapy with concurrent taxane-based chemotherapy for locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2010;77(2):468–76.CrossRefPubMed
28.
go back to reference Boomsma MJ, Bijl HP, Langendijk JA. Radiation-induced hypothyroidism in head and neck cancer patients: a systematic review. Radiother Oncol. 2011;99(1):1–5.CrossRefPubMed Boomsma MJ, Bijl HP, Langendijk JA. Radiation-induced hypothyroidism in head and neck cancer patients: a systematic review. Radiother Oncol. 2011;99(1):1–5.CrossRefPubMed
29.
go back to reference Hancock SL, Cox RS, McDougall IR. Thyroid diseases after treatment of Hodgkin's disease. N Engl J Med. 1991;325(9):599–605.CrossRefPubMed Hancock SL, Cox RS, McDougall IR. Thyroid diseases after treatment of Hodgkin's disease. N Engl J Med. 1991;325(9):599–605.CrossRefPubMed
30.
go back to reference Norris AA, Amdur RJ, Morris CG, Mendenhall WM. Hypothyroidism when the thyroid is included only in the low neck field during head and neck radiotherapy. Am J Clin Oncol. 2006;29(5):442–5.CrossRefPubMed Norris AA, Amdur RJ, Morris CG, Mendenhall WM. Hypothyroidism when the thyroid is included only in the low neck field during head and neck radiotherapy. Am J Clin Oncol. 2006;29(5):442–5.CrossRefPubMed
31.
go back to reference Bhandare N, Kennedy L, Malyapa RS, Morris CG, Mendenhall WM. Primary and central hypothyroidism after radiotherapy for head-and-neck tumors. Int J Radiat Oncol Biol Phys. 2007;68(4):1131–9.CrossRefPubMed Bhandare N, Kennedy L, Malyapa RS, Morris CG, Mendenhall WM. Primary and central hypothyroidism after radiotherapy for head-and-neck tumors. Int J Radiat Oncol Biol Phys. 2007;68(4):1131–9.CrossRefPubMed
32.
go back to reference Lo Galbo AM, de Bree R, Kuik DJ, Lips PT, Mary B, Von Blomberg E, Langendijk JA, Leemans CR. The prevalence of hypothyroidism after treatment for laryngeal and hypopharyngeal carcinomas: are autoantibodies of influence? Acta Otolaryngol. 2007;127(3):312–7.CrossRefPubMed Lo Galbo AM, de Bree R, Kuik DJ, Lips PT, Mary B, Von Blomberg E, Langendijk JA, Leemans CR. The prevalence of hypothyroidism after treatment for laryngeal and hypopharyngeal carcinomas: are autoantibodies of influence? Acta Otolaryngol. 2007;127(3):312–7.CrossRefPubMed
33.
go back to reference Lin Z, Chen L, Fang Y, Cai A, Zhang T, Wu VWC. Longitudinal study on the correlations of thyroid antibody and thyroid hormone levels after radiotherapy in patients with nasopharyngeal carcinoma with radiation-induced hypothyroidism. Head Neck. 2014;36(2):171–5.CrossRefPubMed Lin Z, Chen L, Fang Y, Cai A, Zhang T, Wu VWC. Longitudinal study on the correlations of thyroid antibody and thyroid hormone levels after radiotherapy in patients with nasopharyngeal carcinoma with radiation-induced hypothyroidism. Head Neck. 2014;36(2):171–5.CrossRefPubMed
Metadata
Title
Development of a normal tissue complication probability (NTCP) model for radiation-induced hypothyroidism in nasopharyngeal carcinoma patients
Authors
Ren Luo
Vincent W. C. Wu
Binghui He
Xiaoying Gao
Zhenxi Xu
Dandan Wang
Zhining Yang
Mei Li
Zhixiong Lin
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2018
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-018-4348-z

Other articles of this Issue 1/2018

BMC Cancer 1/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine